A quinoline and tetrazole derivative that acts as a phosphodiesterase type 3 inhibitor, with anti-platelet and vasodilating activity. It is used in the treatment of PERIPHERAL VASCULAR DISEASES; ISCHEMIC HEART DISEASE; and in the prevention of stroke.
Cilostazol has been studied across 24 research domains including ❤️ Cardiovascular, 🔬 Inflammation, 🔥 Metabolic, 🔬 Oncology, ⏳ Longevity & Aging. The primary research focus is ❤️ Cardiovascular with 25% of studies addressing this area.
The following compounds share molecular targets with Cilostazol, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.
This evidence profile for Cilostazol is generated deterministically from 297 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.